Risk Factors for Rivaroxaban-Related Bleeding Events—Possible Role of Pharmacogenetics: Case Series

Non-vitamin K antagonist oral anticoagulants’ interindividual trough concentration variability affects efficacy and safety, especially in bleeding events. Rivaroxaban is metabolised via CYP3A4/5-, CYP2J2-, and CYP-independent mechanisms and is a substrate of two transporter proteins: ABCB1 (MDR1, P-...

Descripción completa

Detalles Bibliográficos
Autores principales: Šimičević, Livija, Slišković, Ana Marija, Kirhmajer, Majda Vrkić, Ganoci, Lana, Holik, Hrvoje, Palić, Jozefina, Samardžić, Jure, Božina, Tamara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966833/
https://www.ncbi.nlm.nih.gov/pubmed/36827667
http://dx.doi.org/10.3390/pharmacy11010029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966833/
https://www.ncbi.nlm.nih.gov/pubmed/36827667
http://dx.doi.org/10.3390/pharmacy11010029

Ejemplares similares